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Summary 
In Alzheimer's disease  (AD), affected neurons accumulate 13 amyloid protein, components of 
which can induce mouse microglia to express the high-output isoform of nitric oxide synthase 
(NOS2) in vitro. Products of NOS2 can be neurotoxic. In mice, NOS2 is normally suppressed 
by transforming growth  factor 131  (TGF-]31). Expression of TGF-131  is  decreased in brains 
from AD patients, a situation that might be permissive for accumulation of NOS2.  Accord- 
ingly, we investigated the expression of NOS2 in patients with AD, using three monospecific 
antibodies: a previously described polyclonal and two new monoclonal antibodies. Neurofibril- 
lary tangle-bearing neurons and neuropil threads contained NOS2 in brains from each of 11 
AD patients ranging in age from 47 to 81 years. NOS2 was undetectable in brains from 6 con- 
trol subjects aged 23-72  years, but was  expressed in small  amounts in 3 control subjects aged 
77-87 years. Thus, human neurons can express NOS2 in vivo. The high-output pathway of 
NO production may contribute to pathogenesis in AD. 
zheimer's disease  (AD) 1 is a chronic form of neurode- 
generation  characterized by progressive memory loss 
and  other intellectual and  emotional dysfunctions leading 
to severe dementia. The most common form of  AD is non- 
dominantly inherited (NDAD), whereas a small percentage 
of patients suffer from familial AD  (FAD). Histopathologi- 
cally,  the  most  prominent  features  of AD  are  neuritic 
plaques  (NP)  and  neurofibrillary tangles  (NFT).  Tangle- 
bearing neurons, which are thought to be degenerating, are 
found predominantly in the entorhinal cortex, hippocam- 
pus,  and  association  cortex.  Both  NP  and  NFT  can  be 
found  in  brains  of the  nondemented  elderly,  albeit  to  a 
lesser extent than in patients with AD (1). 
13 Amyloid protein (A13) accumulates extraceUularly, but 
also  accumulates in NFT (1).  The appearance of AD-like 
pathology in mice transgenic for A13 precursor protein (2) 
IAbbreviations used in this paper: A13, 13 amyloid; AD, Alzheimer's disease; 
FAD, familial AD; NDAD, nondominant  AD; NFT, neurofibrillary  tan- 
gles; NO, nitric oxide;  NOS, NO synthase; NP, neuritic  plaques. 
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supports the hypothesis that A13 contributes to the patho- 
genesis of AD. A13-derived peptides triggered nitric oxide 
(NO) production from nitric oxide synthase (NOS) type 1 (3), 
a NOS isoform expressed constitutively in cerebellar neu- 
rons.  In vitro studies  have implicated NOS1  in neuronal 
injury associated with  excitotoxicity and  ischemia  (4,  5). 
Together  with  cytokines,  A13-derived  peptides  also  in- 
duced  expression of the  high-output  isoform,  NOS2,  in 
mouse microglia (6).  NOS inhibitors protect neurons and 
oligodendrocytes from injury caused by inflammatory cy- 
tokines, bacterial products, and/or A13 in vitro (5-7), sug- 
gesting  that  the  injury is  dependent  on  the  induction  of 
NOS2. 
TGF-131, a potent suppressor of the expression of NOS2 
(8-10), is neuroprotective in various contexts (11-14) and 
suppresses  the  NO-dependent  toxicity inflicted  by  acti- 
vated microglia on  oligodendrocytes (7).  TGF-131  is  de- 
creased in microglia of rats of increasing age concomitantly 
with increased NOS activity (15).  We and others recently 
observed that expression of TGF-IBI is deficient in brains 
of patients with AD (16,  17). Reasoning that this decrease 
in TGF-131 might be permissive for an increased expression 
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Cause of death or 
Donor  Age/sex  Classification  Duration*  Medications  other diagnoses 
)/r 
1  23/M  Control  -- 
2  35/M  Control  -- 
3  62/M  Control  -- 
4  67/M  Control  -- 
5  68/M  Control 
6  72/M  Control 
7  77/M  Control 
8  87/F  Control 
9  87/M  Control 
10  47/M  FAD  8 
11  59/M  FAD  8 
12  81/F  FAD  23 
13  61/M  NDAD  12 
F 
14  63/M  NDAD  14  None 
15  65/F  NDAD  5  Dilantin 
16  65/M  NDAD  Unknown  None 
17  69/M  NDAD  I0  Dilantin 
18  72/M  NDAD  1.5  None 
19  73/M  NDAD  7 
20  79/M  NDAD  6 
None  Anaphylaxis 
None  Viral pneumonia 
Unknown  Prostate cancer 
Unknown  Gastrointestinal 
hemorrhage 
Unknown  Cardiac arrest 
Unknown  Ruptured aneurysm 
Unknown  Ruptured aneurysm 
Unknown  Unknown 
Unknown  Gastrointestinal 
hemorrhage 
Dilantin, Synthroid,  Unknown 
antidepressants 
None  Pneumonia 
Synthroid  Pneumonia 
None  Ethanol intoxication, 
cardiac arrest 
Pneumonia 
Unknown 
Unknown 
Pneumonia 
Acute myocardial 
infarction 
Cardiac arrest  Ativan, Inderal, 
coumadin 
Unknown  Pneumonia 
*With respect to signs or symptoms  of AD. 
of NOS2  in  response  to  AI3  and/or  other stimuli,  we  ex- 
amined AD and control brains for NOS2. 
Materials and Methods 
Patients.  The patient population was drawn from that used in 
a  previous  study  (16).  NDAD  was  considered  to  be  present  in 
eight subjects (mean age 69 yr; range 62-79 yr) who met the Na- 
tional  Institute  of Neurological  and  Communicative  Disorders 
and  Stroke/AD  and  Related  Disorders  Association  criteria  for 
probable AD (18)  without FAD, FAD brains were obtained from 
three patients  (47,  59,  and 81  yr old)  with early-onset dementia 
who had a genetic abnormality on chromosome 14q24.3 (16,  17). 
The patients with FAD were not first- or second-generation rela- 
tives, but they were all from the NIH2 or FAD3 families, which 
have a very distant common relative. All brains from the NDAD 
and FAD groups met Consortium to Establish a Registry for AD 
(CERAD) pathological criteria for AD (19). Control brains (n =  9) 
were obtained from individuals (mean age 64 yr; range 23-87 yr) 
who exhibited no  cognitive or neurological disorders  (Table  1). 
Brains were removed after a postmortem  delay of 1.5-36  h  and 
processed as described (16). 
Antibodies.  NO53, a rabbit antiserum raised against the mod- 
ified human  NOS2-derived  peptide  C-R-NIe-Om-SLEMSAL, 
was  described  (20).  Binding of NO53  can be  competitively in- 
hibited  in radioimmunoassay,  immunocytochemistry,  or immu- 
noblot by the cognate peptide YRASLEMSAL, which incorpo- 
rates SLEMSAL from human NOS2, Tyr for iodination, Arg for 
solubility,  and  Ala  as  a  spacer.  The  control  (truncated)  peptide 
YRASLEMSA, lacking the COOH-terminal Leu, is 10,000-fold 
less effective at binding NO53 by radioimmunoassay and does not 
block NO53 in immunocytochemical or imnmnoblot assays (not 
shown). Thus, YRASLEMSA served as a blocking control. Puri- 
fied recombinant human NOS2 was injected into mice, hybrido- 
mas were produced by standard  methods,  and their supernatants 
were screened against purified human  NOS2 by ELISA. The re- 
sulting mAbs were further screened by immunoblot (see  below). 
1426  NOS2 Expression in Alzheimer's Disease Two were specific for NOS2:1E8-B8 (IgG1 K) and 21C10-1D10 
(IgG2b K) (Research & Diagnostic Antibodies, Richmond, CA). 
These were used either in the form of culture supernate or ascites. 
Rabbit anti-human NOS1  was  raised  against the  peptide  Cys- 
RLRSESIAFIEESKKDTDEVSFSS, in which  Cys  modifies the 
COOH-terminal sequence ofhuNOS1. Rabbit anti-human NOS3 
(C-20,  polyclonal IgG;  Santa Cruz Biotechnology,  Santa  Cruz, 
CA) was raised against amino acids 1183-1202 ofhuNOS3. 
Immunoblot Analysis.  The specificity of NO53  (20),  1E8-B8, 
and 21C10-1D10 for NOS2 was tested by immunoblot analysis 
of human renal epithelial 293 cells (American Type Culture Col- 
lection,  Rockville,  MD)  transiently transfected  by  the  calcium 
phosphate method with the cDNA of human NOS2  (21)  (a gift 
of Dr.  T. Billiar, University of Pittsburgh, Pittsburgh, PA),  hu- 
man NOS1  (22),  or human NOS3 (23)  (both gifts ofP. Marsden, 
University of Toronto,  Toronto,  Canada)  in  the  pcDNAI  or 
pcDNAI/Amp vector (Invitrogen, San Diego, CA). Mock trans- 
fection served as  a  control.  Lysates  were  electrophoresed  under 
denaturing, reducing conditions on pre  cast  4-20%  polyacryla- 
mide gels  (Novex,  San Diego,  CA) in the case  of immunoblots 
with NO53 or on 7.5% polyacrylamide gels in the case ofimmu- 
noblots  with  the  other  antibodies,  transferred  to  nitrocellulose 
membranes (Schleicher & Schuell, Inc., Keene, NH), and probed 
with NO53  at a dilution of 1:10,000; with anti-huNOS2 mAbs 
at l:400 or l:500 dilution of ascites;  anti-huNOS1 at 1:5,000 di- 
lution; or with anti-huNOS3 at 1:1,000 dilution. Bound rabbit Ig 
was  detected with goat anti-mouse IgG coupled to  horseradish 
peroxidase  (Kirkegaard & Perry Laboratories, Inc., Gaithersburg, 
MD) in the case of NO53 or with donkey anti-rabbit IgG conju- 
gated  with  horseradish peroxidase  (Amersham Corp.,  Arlington 
Heights,  IL)  in the other cases,  whereas mouse Ig was  detected 
with sheep anti-mouse IgG conjugated with horseradish peroxi- 
dase  (Amersham Corp.).  Both types of Ig were  revealed by en- 
hanced chemiluminescence, using kits from Amersham Corp. in 
the case of NO53 or Dupont (Boston, MA) for the rest. 
Immunocytochemistry.  Immunocytochemical  analysis  was  es- 
sentially as described for TGF-I3 (16). Briefly, tissue sections were 
deparai~  at 65~  followed by incubation in xylene and eth- 
anol.  After  blocking endogenous peroxidase  activity in 1-1202/ 
methanol and nonspecific binding in 5% BSA/1%  normal goat 
serum, sections were incubated overnight at 4~  with NO53 se- 
rum at a dilution of 1:10,000, with 1E8-B8 ascites at a dilution of 
1:1,000  or  culture  supernatant  at  a  dilution  of  1:50,  or  with 
21C10-1D10 culture supernatant at a dilution of 1:100. Controls 
for specificity of NO53 were normal rabbit serum; NO53 incu- 
bated overnight at 4~  with  15  ~g/ml of peptide YRASLEM- 
SAL,  or NO53  incubated overnight at  4~  with  15  Ixg/ml of 
peptide YRASLEMSA. Bound antibodies were detected with bio- 
tinylated goat anti-rabbit or horse anti-mouse secondary antibod- 
ies followed by horseradish peroxidase conjugated to streptavidin 
(Vector Laboratories, Inc., Burlingame, CA). The complexes were 
visualized using 3,3'-diaminobenzadine (Sigma Chemical Co., St. 
Louis, MO) as chromagen and CuSO  4 as enhancer. Sections were 
counterstained with Meyer's hematoxylin. 
Staining  for NFT, NP, and A~.  To compare NOS2 expression 
with  the  presence  of NFT and  NP,  serial 4-1*m  sections were 
stained for NOS2 or by Bielchowsky's silver method (24)  (Amer- 
ican Histolabs,  Gaithersburg, MD).  AI3 was  detected in sections 
previously stained for NOS2 with NO53 by counterstaining for 4 
rain  with  1.0%  aqueous  thioflavin  S  (Polysciences  Inc.,  War- 
rington, PA). Slides were then rinsed with 80% ethanol followed 
by water, mounted with Uvak mountant (BioMedical Specialties, 
Santa Monica, CA), and viewed under fluorescent light. Stained 
Figure 1.  Specificity  of anti-human NOS2 Abs. Human renal epithe- 
lial 293  cells were  mock transfected (293) or transfected with plasmids 
containing cDNAs for human NOS1, NOS2,  or NOS3.  Lysates of the 
cells containing  NOS1  (75 lag), NOS2 (15 lag for NO53 blot; 140 lag for 
the rest), NOS3 (200 lag) or mock-transfected 293 cells (15 lag for the 
NO53 blot;  120 lag for the rest) were subjected to SDS-PAGE and im- 
munoblotted with  the  indicated  antibodies.  (A)  Specificity of NO53, 
1E8-B8, and 21C10-1D10  for NOS2.  (/7) Recognition of NOS1  and 
NOS3  by isoform-specific antibodies.  Numbers indicate  the  apparent 
molecular masses of protein standards in kilodaltons. 
sections  were  imaged  with  a  video  capture  board  (PixelHr24; 
Perceptics,  Knoxville,  TN)  connected  to  an Apple  Macintosh 
Centris 650 computer using Adobe Photoshop 2.5.1. 
Data Analysis.  The average number of NOS2-positive neu- 
rons  per  field  and  average  percentage  of neurons  positive  for 
NOS2  were  scored  by  a  pathologist  analyzing the  data  in  a 
blinded fashion in five alternating X400 fields (i.e., each counted 
field  was  followed  by an uncounted field)  from  regions  CA1- 
CA3 of the hippocampus. The same sections were scored for ex- 
tent of neuropil threads as follows: grade 0  =  0 per X200 field; 
grade  1  =  1-5 per X200 field; grade 2  =  6-20 per X200 field; 
grade  3  =  >20  per  X200  field.  All values are  mean  +  SEM. 
Where indicated, data were analyzed for significance by the two- 
tailed Student's t test. The Wilcoxon rank--sum test was used to 
analyze the statistical significance of differences in the number of 
NOS2-positive neurons among the groups  examined. Neuropil 
thread  staining was  analyzed using the  Kruskal-Wallis one-way 
analysis of variance by ranks. 
Results 
Antibodies.  Undl recendy, a  rate-limiting step in evalu- 
ation  of the  possible  role  of the  high-output  pathway  of 
1427  Vodovotz et al. 1428  NOS2 Expression in Alzheimer's Disease Figure 3.  Immunocytochemistry  with anti-NOS2 mAbs gives a similar pattern  of staining to NO53.  (A) Hippocampus,  NDAD (patient  17), stained 
with NO53. (B) Same as A but stained with 1EBB8. (Inset) 1ESB8-positive neuron at original magnification of ￿  1,000.  (C) Hippocampus,  FAD (patient 
12), stained with NO53.  (D) Same as C but stained with 21C10-1D10.  (Inset) 21C10-1D10-positive neuron at original magnification  of ￿  (E) 
Hippocampus,  control (subject 1), stained with 1E8B8. (F) Same as E, 21C10-1D10.  ￿ 
NO  production in human  disease has been the lack of anti- 
bodies  demonstrably  specific for human  NOS2.  This work 
made use ofNO53,  a recendy characterized polyclonal an- 
tibody  specific  for  a  COOH-terminal  epitope  of human 
NOS2  (20),  and  two new mAbs raised against  purified re- 
combinant  human  NOS2.  Fig.  1 A  demonstrates  that these 
reagents  immunoblotted  no  proteins  in  human  epithelial 
cells that  were  mock  transfected  or,  in  the  case  of 1E8B8 
Figure 2.  Immunocytochemistry  with NO53.  (A) Frontal cortex,  NDAD (patient  13) stained with NO53.  (Inset) NO53-positive neuron at original 
magnification of X 1,000. (B) Same as A but stained with nonimmune rabbit serum. (C) Same region as A, but stained with NO53 together with control 
peptide  YRASLEMSA. (D) Same region as A, but stained with NO53 together with blocking peptide  YRASLEMSAL.  (E and F) Senile plaques with 
dystrophic  neurites  stained with NO53.  (E) Hippocampus,  NDAD (patient  16). (P  0  Granule  cell layer,  FAD (patient  12). (G) Hippocampus,  control 
(subject 5). (H) Hippocampus,  elderly control (subject 8). (A-D, v  O  ￿  (E, G-H) ￿ 
1429  Vodovotz et al. Figure 4.  Colocalization of NOS2 with NFT and A[3. (A-D) Serial sections. (A) Amygdala, NDAD (patient 16) stained with NO53.  (B) Same as A 
but with Bielchowsky stain. (C) Hippocampus, NDAD (patient 18) stained  with NO53. (/9) Same as C, but with Bielchowsky  stain. Arrows indicate the 
same neurons stained by both NO53 and Bielschowsky's  reagent. (E) Hippocampus (patient 16) stained  with NO53. (F) Same section as E, stained also by 
thioflavin S for the presence ofAp. X400. 
and 21C10-1D10,  transfected with plasmids encoding hu- 
man  NOS1  or NOS3.  A  previous study has  documented 
that NO53  does not react with NOS1  or NOS3  (20).  Ex- 
pression  of the  latter proteins  was  confirmed by reaction 
with appropriate antibodies as in reference 20 (Fig. 1 B). In 
contrast, in cells transfected with a  human NOS2 plasmid, 
NO53  and both mAbs detected the expected 130-kD band 
(Fig. 1 A). 
NOS2 Immunoreactivity  in AD Brains.  In brains of all eight 
patients with NDAD,  NO53  stained clusters of neurons  as 
well as plaquelike areas of neuropil in a  focal pattern.  Ex- 
pression of NOS2  was most pronounced in tangle-bearing 
neurons  and  neuropil  threads  within  the  hippocampus, 
parahippocampal gyms, amygdala, and frontal cortex (Figs. 
2  and 3).  All three patients with FAD expressed NOS2  in 
neuronal  cell  bodies,  albeit  fewer  than  in  patients  with 
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Quantitation of expression of NOS2. Sections from control  Figure  5. 
subjects (CTRL;  n =  8) and patients with FAD (n =  3) or NDAD (n =  8) 
were stained  with NO53.  (A) Average number of neurons in five alter- 
nating ￿  fields in regions CA1-CA3 of the hippocampus (open bars) 
and average  percentage of NOS2-positive neurons in the same fields (solid 
bars) (means --+  SEM).  Asterisk  denotes statistically  significant  difference 
from control  subjects  (P  <0.05)  by  the  Wilcoxon  rank--sum test.  (B) 
Same sections  as in A were analyzed  for extent of NOS2-positive neuro- 
pil threads  and scored as described  in Materials  and Methods. Open sym- 
bols represent means of 10  contiguous fields in the hippocampus. Hori- 
zontal bars represent median values. Asterisk denotes significant  difference 
from control subjects  (P <0.05). 
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NDAD  (Figs.  2 F  and 3,  C  and D). Staining was most ex- 
tensive in the oldest FAD patient examined (patient 12; see 
Table  1).  This patient  also  exhibited  staining  in  scattered 
neuropil threads throughout the hippocampus. No staining 
was obtained in any subject with normal rabbit serum, as il- 
lustrated in Fig. 2 B, nor with NO53 incubated with an ex- 
cess  of the  cognate  peptide,  as  illustrated  in  Fig.  2  D. 
NO53  staining  was  unaffected by the  control  (truncated) 
blocking peptide  (Fig.  2  C).  mAbs  1E8-B8  and  21C10- 
1D10 gave essentially the same staining pattern as NO53 in 
serial  sections, though staining of neuropil threads was less 
pronounced with the mAbs than with NO53 (Fig. 3, A-D). 
NOS2 Immunoreactivity in Brains  from Neurologically Nor- 
mal Subjects.  Younger (23-72-yr-old) control subjects ex- 
pressed no NOS2 protein in the cerebellum, frontal cortex, 
hippocampus,  amygdala,  or  entorhinal  cortex  (Figs.  2  G 
and 3, E  and F). Older (77-87-yr-old) control subjects ex- 
pressed NOS2  in  rare  neurons  in  the  frontal cortex,  hip- 
pocampus,  amygdala,  or  entorhinal  cortex.  Subject  8,  an 
87-yr-old woman who did not fit the CERAD criteria for 
AD (Table 1), expressed NOS2 in neurons, NFT, and NP 
in the medial temporal lobe (Fig.  2 H). An 87-yr-old man 
(subject 9) expressed NOS2 in scattered neurons and neu- 
ropil threads in the amygdala (not shown).  No hippocam- 
pal  sections  were  available  for  staining  in  this  case.  The 
mAbs 1E8-B8 and 21C10-1D10 hkewise stained no cells in 
control brains from subjects <77 yr of age (Pig. 3, E and F). 
Presence of NOS2 in Neurons Bearing Neurofibrillary Tangles 
in Areas Expressing A~.  Neuronal staining for NOS2 in AD 
cases appeared to involve neurons containing NFT (Figs. 2 A 
and  3,  A-D).  To  test  this  impression,  adjacent  4-txm 
sections  of  hippocampus,  amygdala,  and  frontal  cortex 
were stained for NOS2 or with Bielchowsky's silver-based 
method for NP and NFT. Considering the average diameter 
of pyramidal neuronal cell bodies in these regions (~20 t~m), 
it  was  anticipated  that  the  same  neuron  could  be  repre- 
sented in both sections.  As shown in  Fig.  4, A-D,  NOS2 
appeared to  be  expressed predominandy in  neurons  con- 
taining  NFT.  However,  not  all  NP  and  NFT  stained  for 
NOS2.  NOS2  was  expressed in  focal areas  in  which  AI3 
was also expressed (Fig.  4, E  and F). 
Enumeration of NOS2-positive Neurons.  We  next  quan- 
titated  the  proportion  of total  neurons  that  were  NOS2 
positive  within  hippocampal  regions  CA1-CA3  in  cases 
where  these regions were well represented.  Although  the 
total number of neurons in these regions was shghtly lower 
in patients with NDAD and FAD than in controls,  1.7  • 
1.2% of neurons (n =  8) stained positive in controls, 9.2  +- 
2.9% (n =  3) in FAD, and 16.5  •  2.3% (n =  8) in NDAD 
(Fig.  5 A). The density of neuropil threads within the hip- 
pocampus that stained positive for NOS2  was significandy 
increased  in  patients with  NDAD  (median  grade  =  0  for 
controls and 0.8 for NDAD, P  <0.05;  Fig.  5 B). 
Discussion 
In  the  human  central nervous  system,  NOS2  has been 
detected  in  glial  cells  during  cytomegalovirus  infection (25),  in  extracted  brain  tissue  from a  patient  with  AIDS- 
associated cerebritis (26), in reactive astrocytes (27) and ex- 
tracted brain tissue  (28)  from patients with multiple sclero- 
sis, and in brain  microvessels from patients  with AD  (29). 
To our knowledge, the evidence herein is the first to local- 
ize NOS2 to neurons in human brain. NOS2-positive neu- 
rons  were  detected  in  100%  of the  AD  brains  studied. 
NOS2 was undetectable in brains from neurologically nor- 
mal subjects <77 yr old, but was expressed in rare neurons 
in  those  of more  advanced  age.  In  contrast  to  NOS2, 
NOS1  was reported to be expressed  normally in brains  of 
patients with AD (30, 31).  The cerebellum, site of greatest 
expression of NOS1  (4,  5), did not stain with the antibod- 
ies used in this study, further evidence of their specificity. 
In vitro, cytokines, microbial products, and A[~ peptides, 
usually in combination, have induced NOS2 in rodent and 
human microglia and astrocytes (5-7).  However, in brains 
of patients with AD, we did not observe NOS2 in any ceils 
or structures other than neurons and neuropil, although the 
antibodies used are capable of detecting NOS2 in nonneu- 
ronal  ceils,  such  as  macrophages  (20).  Astrocytes and  nil- 
croglia were not immunoreactive,  and we did not confirm 
the reported microvascular localization  (29).  Tangle-bearing 
neurons  stained  most intensely.  The restricted  localization 
suggests  that  at  least  one  factor essential  for expression  of 
NOS2 was probably present  only within  neurons  or only 
active  upon  neurons;  especially  those  that  contained,  or 
came to contain,  aggregates of A~3. Because of the expres- 
sion of NOS2 and A~ in the  same loci  (Fig.  4,  E  and/3, 
we hypothesize that A[3 in conjunction with other inflam- 
matory stimuli  may have  induced  an  enzymatically active 
NOS2. We further suggest that the  deficiency of TGF-~I 
(16,  17)  may have been permissive for sustained expression 
of NOS2,  and that the possible  overproduction of NO  in 
AD  neurons  may  have  been  detrimental  (5)  rather  than 
protective  (32).  It  may be  feasible  to  test  some  of these 
ideas in animal models. 
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